Easing the pressure

LAT Pharma LLC is developing and commercializing a novel treatment for ascites due to liver cirrhosis.

Our new drug candidate, PHT103, with once-daily outpatient dosing, is designed to become the first long-acting agent specifically indicated for the chronic management of this poorly controlled and frequently fatal condition—and the only agent that targets its root cause: portal hypertension.

We thank you for visiting and invite you to Contact Us for more information about our company.

©2014 LAT Pharma LLC


LAT Pharma was founded with the express goal of inventing, developing, and commercializing a lifesaving new therapy for people afflicted with advanced liver disease and liver cirrhosis and its deadly complications.